  Evaluation of prevalence of osteoporosis and osteopenia in men presenting at multiple risk detection campaign; ; Tancredi, Annalisa  et alin Osteoporosis International (2004, May), 15(Suppl.1), 54 Detailed reference viewed: 8 (1 ULg)Evaluation of the relationship between IGF-1, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign; Tancredi, Annalisa ; et alin Osteoporosis International (2004, May), 15(Suppl.1), 48-49 Detailed reference viewed: 10 (4 ULg)Evaluation of the relationship between IGF-I, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign; Tancredi, Annalisa ; et alin Osteoporosis International (2003, November), 14(Suppl. 7), 90-91 Detailed reference viewed: 17 (7 ULg)Evaluation of prevalence of osteoporosis and osteopenia in men presenting at multiple risk detection campaign; ; Tancredi, Annalisa et alin Osteoporosis International (2003, November), 14(Suppl. 7), 90 Detailed reference viewed: 7 (2 ULg) Prevention de la fracture de la hanche chez le sujet age: ou en sommes-nous en 2003?Reginster, Jean-Yves ; Lecart, Marie-Paule ; Sarlet, Nathalie et alin Revue Médicale de Liège (2003), 58(4), 183-90 Osteoporosis in very elderly subjects is now considered, in most developed and several developing countries as a major social, clinical and financial burden. While many compounds have been investigated in ... [more ▼] Osteoporosis in very elderly subjects is now considered, in most developed and several developing countries as a major social, clinical and financial burden. While many compounds have been investigated in the prevention or treatment of spinal fractures, few of them have unequivocally demonstrated their ability to reduce the risk of non vertebral and more specifically hip fractures in the very elderly. This situation may seem highly paradoxical since hip fractures are unanimously considered to be the most dramatic and disabling consequence of osteoporosis. The present article reviews the current evidence available to justify anti-osteoporotic medications to be recommended to very elderly subjects, in the perspective of reducing their risk of appendicular fractures. [less ▲] Detailed reference viewed: 26 (4 ULg)Osteoporosis in the very elderly; Bruyère, Olivier ; Reginster, Jean-Yves in Medicographia (2002), 24(4), 316-321 Detailed reference viewed: 7 (4 ULg)Psychiatrie en osteoporose; Reginster, Jean-Yves in Agenda Psychiatrie (L') (2000), 14 Detailed reference viewed: 7 (1 ULg)Les propriétés de la glucosamineReginster, Jean-Yves ; in Journal de Pharmacie de Belgique (2000), 55(5), 118-121 Detailed reference viewed: 14 (1 ULg)Eigenschappen van glucosamineReginster, Jean-Yves ; in Medi-Sfeer (2000), 116 Detailed reference viewed: 11 (1 ULg)Le capital osseux : une épargne qui débute au berceau; Reginster, Jean-Yves in L'agenda Pédiatrie (2000), 22 Detailed reference viewed: 8 (1 ULg)Het botkapitaal : een spaarboekje dat in de wieg begint; Reginster, Jean-Yves in De Agenda Pediatrie (2000), 22 Detailed reference viewed: 7 (1 ULg)Preventie van postmenopauzale osteoporoseReginster, Jean-Yves ; in De agenda Gynaecologie (2000), 19 Detailed reference viewed: 2 (1 ULg)Calcitonine dans la prévention secondaire et tertiaire de l’ostéoporose; Reginster, Jean-Yves in Medi-Sphere (1999), 3 Detailed reference viewed: 8 (2 ULg)Established postmenopausal osteoporosis – Assessment of treatment optionsReginster, Jean-Yves ; ; et alin Menopause Review (1999), 1(IV), 39-55 Detailed reference viewed: 3 (1 ULg)Treatment of Osteoporosis: Role of Bone-Forming AgentsReginster, Jean-Yves ; ; Henrotin, Yves et alin Osteoporosis International (1999), 9 Suppl 2 Detailed reference viewed: 2 (1 ULg)Efficacy and Tolerability of Calcitonin in the Prevention and Treatment of Osteoporosis; Reginster, Jean-Yves in BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals & Gene Therapy (1998), 10(4), 295-300 Calcitonin in general, and, more specifically, salmon calcitonin (salcatonin), has been known for 30 years to be a specific inhibitor of bone resorption. Studies have confirmed its efficacy in metabolic ... [more ▼] Calcitonin in general, and, more specifically, salmon calcitonin (salcatonin), has been known for 30 years to be a specific inhibitor of bone resorption. Studies have confirmed its efficacy in metabolic bone diseases characterised by excessive bone resorption, such as osteoporosis. Most randomised studies in which salcatonin and oral calcium were administered for 1 to 5 years to recently postmenopausal women for the prevention of osteoporosis have shown that bone mineral density or bone content of the lumbar spine increased significantly, compared with a reduction among women receiving calcium only. Prospective studies have shown that salcatonin is effective in the treatment of established osteoporosis, reducing significantly the relative risk of new vertebral fractures. The benefits of salcatonin nasal spray therapy were observed in the majority of women studied, and it has been shown to be an effective alternative for osteoporotic women more than 5 years postmenopausal who refuse estrogens, or for whom estrogens are contraindicated. Finally, in established osteoporosis, nasal calcitonin possesses a potent analgesic effect. The well-demonstrated effects of nasal calcitonin permit it to be considered a well tolerated and efficient approach for prevention and treatment of postmenopausal osteoporosis. [less ▲] Detailed reference viewed: 5 (4 ULg)Le cas clinique du mois. Ostéoporose et beta-thalassémie; ; et al in Revue Médicale de Liège (1997), 52(3), 138-41 Detailed reference viewed: 8 (2 ULg)The role of bisphosphonates in the treatment of osteoporosisReginster, Jean-Yves ; ; Gosset, Christiane et alin Drugs of Today (Barcelona, Spain : 1998) (1997), 33 Detailed reference viewed: 8 (0 ULg) |
||
